3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Rare Diseases
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Genetic Predisposition to Disease
1
Interventions
blinatumomab
3
Blood Specimen Collection
2
Azacitidine
2
venetoclax
1
ivosidenib
1
gilteritinib
1
daratumumab
1
avapritinib
1
Transplantation
1
Radiosurgery
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Lenalidomide
1
Interferon alpha-2
1
Inotuzumab Ozogamicin
1
Idarubicin
1
High-Throughput Nucleotide Sequencing
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
Consolidation Chemotherapy
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Neoplasm, Residual
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT02339805
2017-07-07
LymphoSeq
Centre Henri Becquerel
Phase NA
Completed
30 enrolled